[go: up one dir, main page]

MX2012001419A - Compuestos biciclicos novedosos de urea. - Google Patents

Compuestos biciclicos novedosos de urea.

Info

Publication number
MX2012001419A
MX2012001419A MX2012001419A MX2012001419A MX2012001419A MX 2012001419 A MX2012001419 A MX 2012001419A MX 2012001419 A MX2012001419 A MX 2012001419A MX 2012001419 A MX2012001419 A MX 2012001419A MX 2012001419 A MX2012001419 A MX 2012001419A
Authority
MX
Mexico
Prior art keywords
urea compounds
novel bicyclic
bicyclic urea
novel
cancer
Prior art date
Application number
MX2012001419A
Other languages
English (en)
Inventor
Brian L Hodous
Ruoxi Lan
Srinivasa R Karra
Bayard R Huck
Amanda E Sutton
Andreas Goutopoulos
Xiaoling Chen
Reinaldo C Jones
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2012001419A publication Critical patent/MX2012001419A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención proporciona compuestos azaheterocíclicos sustituidos novedosos de acuerdo con la Fórmula (I), su manufactura y su uso para el tratamiento de enfermedades hiperproliferativas, tales como el cáncer.
MX2012001419A 2009-08-06 2010-07-28 Compuestos biciclicos novedosos de urea. MX2012001419A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23187309P 2009-08-06 2009-08-06
PCT/US2010/043467 WO2011017142A1 (en) 2009-08-06 2010-07-28 Novel bicyclic urea compounds

Publications (1)

Publication Number Publication Date
MX2012001419A true MX2012001419A (es) 2012-03-16

Family

ID=42985363

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001419A MX2012001419A (es) 2009-08-06 2010-07-28 Compuestos biciclicos novedosos de urea.

Country Status (14)

Country Link
US (1) US8569295B2 (es)
EP (1) EP2461869B1 (es)
JP (1) JP5718332B2 (es)
KR (1) KR20120055608A (es)
CN (1) CN102573994B (es)
AU (1) AU2010281368C1 (es)
CA (1) CA2770156C (es)
EA (1) EA201200218A1 (es)
ES (1) ES2433230T3 (es)
IL (1) IL217651A (es)
MX (1) MX2012001419A (es)
SG (1) SG178271A1 (es)
WO (1) WO2011017142A1 (es)
ZA (1) ZA201201635B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110075016A (ko) 2008-10-14 2011-07-05 닝 시 화합물 및 사용 방법
EP2408300B1 (en) 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
SG190735A1 (en) 2011-02-28 2013-07-31 Calitor Sciences Llc Substituted quinoline compounds and methods of use
WO2013022519A1 (en) * 2011-08-10 2013-02-14 Merck Patent Gmbh Pyrido-pyrimidine derivatives
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
RU2650895C2 (ru) 2012-07-28 2018-04-18 Саншайн Лейк Фарма Ко., Лтд. Соединения замещенных пиразолонов и способы использования
US8975282B2 (en) 2012-07-28 2015-03-10 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
EP2890380A2 (en) 2012-08-29 2015-07-08 Merck Patent GmbH Ddr2 inhibitors for the treatment of osteoarthritis
WO2015057659A1 (en) 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
RU2671496C2 (ru) 2013-10-14 2018-11-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные 5-пиперидин-8-цианохинолина
CN106279147A (zh) 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
US11096909B2 (en) 2016-04-06 2021-08-24 University Of Oulu Compounds for use in the treatment of cancer
CA3064975A1 (en) * 2017-05-26 2018-11-29 Glenmark Pharmaceuticals S.A. Novel inhibitors of map4k1
GB2575490A (en) 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
CN110857293B (zh) * 2018-08-24 2023-01-10 药捷安康(南京)科技股份有限公司 一种新型的喹啉衍生物抑制剂
US12378245B2 (en) * 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
CN112625026B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 Tam家族激酶抑制剂的喹啉衍生物
CA3178450A1 (en) 2020-03-30 2021-10-07 Hutchison Medipharma Limited Amide compounds and uses thereof
CN112225748B (zh) * 2020-10-20 2021-11-30 四川大学华西医院 一种具有flt3激酶抑制活性的小分子化合物及其应用
WO2022175514A1 (en) 2021-02-22 2022-08-25 Bayer Aktiengesellschaft N-(pyridin-2-yl)-acetamides as p2x3 inhibitors
KR102726416B1 (ko) * 2021-12-15 2024-11-05 한국과학기술연구원 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 피리도피리미딘 유도체 및 이들의 용도
MX2024007444A (es) 2021-12-16 2024-09-02 Kinnate Biopharma Inc Inhibidores de cinasa met.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04011579A (es) * 2002-05-29 2005-03-07 Amgen Inc Derivados de 2-oxo-2,3,4-trihidroquinazolinilo para el tratamiento de trastornos relacionados con la proliferacion celular.
DE102004004731A1 (de) * 2004-01-30 2005-08-18 Merck Patent Gmbh Harnstoffderivate
EP1858889A1 (en) * 2005-03-08 2007-11-28 Biota Scientific Management Pty. Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
ZA200710379B (en) * 2005-05-20 2009-05-27 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase

Also Published As

Publication number Publication date
AU2010281368C1 (en) 2016-08-04
CN102573994B (zh) 2015-06-24
JP5718332B2 (ja) 2015-05-13
US8569295B2 (en) 2013-10-29
AU2010281368B2 (en) 2016-04-14
CA2770156A1 (en) 2011-02-10
SG178271A1 (en) 2012-03-29
AU2010281368A1 (en) 2012-03-22
KR20120055608A (ko) 2012-05-31
EP2461869B1 (en) 2013-08-21
IL217651A (en) 2017-08-31
US20120190654A1 (en) 2012-07-26
EP2461869A1 (en) 2012-06-13
CN102573994A (zh) 2012-07-11
EA201200218A1 (ru) 2012-09-28
JP2013501047A (ja) 2013-01-10
ZA201201635B (en) 2012-11-28
CA2770156C (en) 2019-02-12
WO2011017142A1 (en) 2011-02-10
ES2433230T3 (es) 2013-12-10

Similar Documents

Publication Publication Date Title
MX2012001419A (es) Compuestos biciclicos novedosos de urea.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
MY160468A (en) Novel amino azaheterocyclic carboxamides
MX2013005751A (es) Quinazolincarboxamida azetidinas.
MX2014002836A (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
WO2012013282A8 (en) Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k
MX2011009780A (es) Pirimidinas sustituidas para el tratamiento del cancer.
MY151342A (en) Phenylamino isonicotinamide compounds
IN2012DN02081A (es)
SG176015A1 (en) Antiviral compounds
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
SG190785A1 (en) Antiviral compounds
MX2013010898A (es) Novedoso derivados de la pirimidina.
TN2011000259A1 (en) Substituted pyrimidines for the treatment of diseases such as cancer
PH12013501600A1 (en) Novel heterocyclic derivatives
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
MX2014002832A (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
MX2011008899A (es) Nuevas orto-aminoamidas para el tratamiento del cancer.
MX343377B (es) Carboxamidas azaheterocilcicas de amina ciclica.
WO2014086453A8 (en) Azaheterobicyclic compounds
MX353062B (es) Nuevas carboxamidas heterociclicas como moduladores de la activadad de cinasas.
NZ609924A (en) Porphyrin treatment of neurodegenerative diseases
TN2010000583A1 (en) Organic compounds
MX2010009382A (es) Derivados de 4-aminociclohexano sustituidos para tratamiento de dolor.